Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark

First commercial test for SARS-CoV-2 will enable expedited coronavirus testing to meet urgent medical needs
Testing on widely available, high-volume cobas 6800/8800 will significantly increase available testing capacity
Roche expedites test development to support urgent need for patient testing during pandemic outbreak to avoid a further spread of the virus at an early stage of infectionContinue reading

SynCardia Systems, LLC. 50cc temporary Total Artificial Heart (TAH-t) Now FDA Approved

With the FDA approval of the SynCardia Systems, LLC 50cc TAH-t system a greater number of cardiac transplant eligible patients at risk of imminent death from biventricular failure now have access to total artificial heart therapy.
The 50cc TAH-t is 37.5% smaller than the 70cc device while maintaining a peak cardiac output of 7.5 liters per minute making it ideally suited for smaller statured adults and pediatric patients.Continue reading

Tech Launch Arizona Kicks Off Entrepreneurial Fellowship Program

Tech Launch Arizona (TLA) recently launched the newly developed Student Entrepreneurial Fellowship Program. The fellows comprise a team of four qualified candidates from a diverse range of backgrounds who are eager to make the most of this rare opportunity. Over the course of their employment with TLA they will work closely with the venture development team and gain valuable experience in the startup assessment and launch process.Continue reading

Phoenix Based Paradigm And Viomics Acquired by Exact Sciences

On March 3, 2020, Exact Sciences Corp. (NASDAQ: EXAS) announced the completion of its acquisitions of Paradigm Diagnostics, Inc. and Viomics, Inc., two privately held companies based in Phoenix. Together, Paradigm and Viomics provide a differentiated late-stage therapy selection test and deep competencies in sequencing and biomarker discovery, extending Exact Sciences’ lab testing and research and development capabilities.Continue reading

New FDA Guidance Issued for Clinical Laboratory Improvement Amendments (CLIA) Waiver Applications

On February 25, 2020, the FDA issued two Clinical Laboratory Improvement Amendments (CLIA) Waiver Applications related final guidance documents.

Continue reading

COVID-19 – Government and Industry Work Together to Address a Global Health Emergency

Biotech and Medtech innovators are working to find answers and provide support for people impacted by the Novel Corona Virus (COVID-19). As they work for develop and deliver solutions, get the latest on what you should know, situation updates and key information for travelers, healthcare professionals, the businesses from the Centers for Disease Control at the CDC Information Hub

Continue reading

Avery Therapeutics Co-founder and Chief Executive Officer named a Senior Member of the National Academy of Inventors

Jordan Lancaster is an assistant research scientist with the Sarver Heart Center and founder of Avery Therapeutics, which aims to advance tissue-engineered therapeutics to treat heart disease and muscle injuries. He holds three U.S. patents. Lancaster’s technologies include MyCardia, which is designed to make new blood vessels and “re-muscularize” the heart, making it perform better.Continue reading